CITF Research Results

CITF Research Results2021-02-24T12:46:09-05:00

COVID Symptoms, Seroprevalence, and Mortality During the First Wave of SARS-CoV-2 in Canada

A large group of researchers found seroprevalence across Canada was low in the first wave of the pandemic but found 31% of those who tested positive for antibodies had never had symptoms. They also found the death rate in nursing homes was over 70 times greater than among elderly adults living outside of nursing homes.

January 25, 2021|Seroprevalence studies|

Latest findings reveal few Canadian adults have antibodies to SARS-Cov-2

Canadian Blood Services and the CITF’s collaborative nine-province SARS-CoV-2 seroprevalence study for October thru November suggests that 1.5 per cent of healthy Canadians had been exposed to SARS-CoV-2. The highest levels were recorded in Western Canada but mass national vaccination remains only route to achieving herd immunity.

January 25, 2021|Media Releases, Seroprevalence studies|

SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline

Researchers from Public Health Ontario and the University of Toronto found that there was a drop in the number of samples with detectable antibodies over time using the Abbott Architect SARS-CoV-2 IgG assay, but not when using the Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG test. The study provides evidence that there exists potentially significant variability in assays, which may give the impression of waning protection against COVID infection.

Systematic examination of antigen-specific recall T cell responses to SARS-CoV-2 versus influenza virus reveals a distinct inflammatory profile

Researchers at the University of Toronto, published in the Journal of Immunology, shed light on what is happening in the body may help to explain why patients with SARS-CoV-2 have more severe inflammation and lung tissue damage than patients suffering from regular seasonal influenza virus.

December 17, 2020|Immune mechanism studies|
Go to Top